Pulmonx Co. (NASDAQ:LUNG) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Pulmonx Co. (NASDAQ:LUNG) have earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $13.36.

LUNG has been the subject of a number of analyst reports. Morgan Stanley initiated coverage on Pulmonx in a research report on Monday, March 10th. They set an “equal weight” rating for the company. Wells Fargo & Company lowered their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. Citigroup assumed coverage on shares of Pulmonx in a research report on Monday, March 10th. They set a “buy” rating on the stock. D. Boral Capital started coverage on shares of Pulmonx in a report on Monday, March 10th. They issued a “buy” rating and a $17.00 target price for the company. Finally, Jefferies Financial Group initiated coverage on shares of Pulmonx in a report on Monday, March 10th. They set a “buy” rating on the stock.

Insider Activity at Pulmonx

In other Pulmonx news, insider Geoffrey Beran Rose sold 5,779 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.13, for a total value of $41,204.27. Following the transaction, the insider now owns 285,278 shares of the company’s stock, valued at approximately $2,034,032.14. This represents a 1.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Steven S. Williamson sold 27,689 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.14, for a total value of $197,699.46. Following the completion of the transaction, the chief executive officer now directly owns 194,342 shares in the company, valued at $1,387,601.88. The trade was a 12.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 147,986 shares of company stock worth $1,143,673 over the last quarter. Company insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Pulmonx

Institutional investors have recently made changes to their positions in the business. 272 Capital LP bought a new stake in Pulmonx during the third quarter valued at approximately $25,000. BNP Paribas Financial Markets purchased a new position in shares of Pulmonx during the 4th quarter worth $43,000. R Squared Ltd bought a new stake in shares of Pulmonx during the 4th quarter valued at $46,000. ProShare Advisors LLC purchased a new stake in shares of Pulmonx in the 4th quarter worth $72,000. Finally, Stifel Financial Corp purchased a new stake in shares of Pulmonx in the 4th quarter worth $81,000. Institutional investors own 91.04% of the company’s stock.

Pulmonx Stock Up 0.7 %

NASDAQ:LUNG opened at $6.79 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The firm’s 50-day moving average price is $7.16 and its 200-day moving average price is $6.96. The company has a market capitalization of $270.21 million, a PE ratio of -4.72 and a beta of 0.50. Pulmonx has a 1-year low of $5.46 and a 1-year high of $10.01.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The business had revenue of $23.77 million for the quarter, compared to analysts’ expectations of $22.29 million. On average, equities analysts predict that Pulmonx will post -1.55 EPS for the current fiscal year.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.